arrow
E

Esther M. Maier

newborn screening
H指数:37
被引数:4,262

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correspondence on “Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)” by Smith et al

关于“苯丙氨酸羟化酶缺乏症的诊断与管理:美国医学遗传学与基因组学学院(ACMG)2023年循证临床指南”的通信,由Smith等人撰写

2026-01-060
PRE
Long-term efficacy and safety of arimoclomol in Niemann-Pick disease type C: Final results of the phase 2/3 NPC-002 48-month open-label extension trial

Arimoclomol在尼曼-皮克病C型中的长期疗效与安全性:NPC-002 48个月开放标签扩展试验2/3期的最终结果

2025-07-070
PRE
Mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase deficiency: From metabolism to clinical implications

线粒体3-羟基-3-甲基戊二酰辅酶A合酶缺乏症:从代谢到临床意义

2025-06-110
OA
Neurological outcome in long-chain hydroxy fatty acid oxidation disorders
2024-01-233
OA
Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire

依格列净治疗Ib型糖原贮积病的疗效和安全性: 来自国际问卷的数据

2022-08-0140
OA
Persistent effect of arimoclomol in patients with Niemann-Pick disease type C: 24-month results from an open-label extension of a pivotal phase 2/3 study

arimoclomol对C型niemann-pick病患者的持续作用: 关键2/3期研究的开放标签扩展的24个月结果

2022-02-010
PRE
The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study (vol 11, 19300, 2021)
2021-10-120
OAAI
Blood DNA methylation provides an accurate biomarker of KMT2B-related dystonia and predicts onset
BRAIN
IF11.7
2021-09-3023
OA
The biochemical subtype is a predictor for cognitive function in glutaric aciduria type 1: a national prospective follow-up study
2021-09-2920
OAAI
Glutaric Aciduria Type I Missed by Newborn Screening: Report of Four Cases from Three Families

新生儿筛查漏诊的I型戊二酸尿症:来自三个家系的四例报告

2021-06-187
OAAI
Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study (vol 15, 328, 2020)
2021-06-011
OAAI
Persistent effect of arimoclomol in patients with Nuemann-Pick disease type C: 12-month results from an open-label extension of a pivotal phase 2/3 study
2021-02-010
PREAI
Clinical disease progression and biomarkers in Niemann-Pick disease type C: a prospective cohort study
2020-11-2315
OAAI
Biallelic MADD variants cause a phenotypic spectrum ranging from developmental delay to a multisystem disorder
BRAIN
IF11.7
2020-08-0619
OAAI